A groundbreaking immunotherapy candidate, now in clinical trials, offers a powerful dual response against cancer. This small molecule increases the activity of immune cells while making tumors more susceptible to immune attack. Developed by researchers...

Immune checkpoint blockade is effective for some patients with cancer, but most are refractory to current immunotherapies and new approaches are needed to overcome resistance1,2. The protein tyrosine phosphatases PTPN2 and PTPN1 are central regulators...